Eton Pharmaceuticals acquires Galzin

Eton Pharmaceuticals (ETON) announced that it has acquired Galzin. Galzin is FDA-approved as a maintenance treatment of patients with Wilson Disease who have been initially treated with a chelating agent. It is estimated that less than 5,000 patients in the United States are currently being treated for Wilson Disease. Eton expects to assume the commercialization of the product in the United States in the first quarter of 2025 with its metabolic sales force supporting healthcare professionals who treat Wilson Disease. Once available, Eton plans to offer the product through its Eton Cares patient support program that provides high-touch, personalized service tailored for rare disease patients and their providers. The program will offer a $0 co-pay for all qualified commercial patients, provide prescription fulfillment, insurance benefits investigation, educational support, and other services designed to help patients access treatment. As part of the transaction, Eton has also acquired European rights to the product, where it is commercialized under the tradename Wilzin by a third party. Under an existing distribution agreement, Eton will continue to supply the product to the third party and the third party is responsible for all commercialization activities in Europe.